A mushroom sold in Asian markets causes remarkably consistent hallucinations of miniature people in 96% of affected individuals, a phenomenon documented independently across China, Papua New Guinea, and the Philippines

Too long to read? Go for the highlights below. Compass Pathways accelerates its planned commercial launch of COMP360 for treatment-resistant depression by up to a year after favourable engagement with the FDA. Phase 3 data remain the decisive hurdle, with key 9-week and 26-week readouts expected in early 2026. Despite rising losses linked to warrant liability adjustments, the company reports a strengthened cash position sufficient to operate into 2027. Regulatory momentum and

Germany has launched the EU’s first regulated psilocybin program , offering hope for those with severe depression but facing hurdles in...

The nation’s first regulated psilocybin market shows promise but faces hurdles in accessibility and cost. In 2020, Oregon became the...

Compass Pathways has become the first company to publish Phase 3 data for a classical psychedelic. Its synthetic psilocybin candidate,...